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ABSTRACT 
Cerebral aneurysms can be found in over 2% of the American population, and their rupture into 
hemorrhagic stroke carries a 40% mortality rate. This makes their treatment important to 
clinicians trying to prevent this from happening to millions of people.  A novel polymer, 
poly(propylene glycol) diacrylate and pentaerythritol tetrakis (3-mercaptopropionate) (PPODA-
QT), has been developed in order to successfully embolize these aneurysms. It is injected 
through a catheter into the aneurysm, where it cures and the aneurysm can heal itself, eliminating 
the risk of rupture and stroke. This thesis focuses on the embolic risks presented during the 
injection and curing of PPODA-QT. 
The first aim of this project was to build an endovascular flow model that could accurately 
mimic conditions found in the human body. This was used to practice procedures and evaluate 
embolic risk. In the second aim, multiple microscopy methods were used to capture and analyze 
particles shed downstream during the procedure to ensure that the injection would be safe for use 
in living models. In the final aim, rabbit aneurysm models were used to confirm that no negative 
embolic effects were observed. 
A model was built that could control pressure, temperature, and pressure.  The model was 
designed with customizable inserts that could be changed to model various anatomies. 
Differential interference contrast (DIC) microscopy was used to analyze filters that captured 
downstream particles produced during the procedure. Feasibility of inline digital holography was 
also performed. Finally, a rabbit aneurysm model was developed in order to treat different 
aneurysm morphologies. This thesis presents a series of methods that can be used to study of the 
embolic risks of a novel aneurysm treatment with the potential to impact millions of lives.  
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CHAPTER 1 
BACKGROUND 
Stroke Disease State 
Stroke is the fifth leading cause of death in the United States, claiming the lives of approximately 
140,000 people per year.1 Strokes can come in two forms: ischemic and hemorrhagic. Ischemic 
strokes occur when clots or foreign particles block vessels and cause ischemia, or an insufficient 
blood supply to regions of the body. Hemorrhagic strokes occur when blood vessels rupture and 
cause internal bleeding and ischemia in downstream tissues. These can be caused by burst 
arteriovenous malformations (AVMs), fistulas, or lesions that expand into aneurysms. Cerebral 
aneurysms, or aneurysms found in the circulatory system of the brain, are especially dangerous. 
There are two main cerebral aneurysm shapes: saccular and fusiform (Figure 1).2 They are found 
in 2% of the US population, and 30,000 of them rupture each year, causing hemorrhagic stroke. 
Of these, 40% are fatal and the remaining 2/3 cause permanent neurological damage.3 The 
enormous consequences of aneurysm rupture makes it a high priority for preventative treatment, 
but unfortunately there are few symptoms of stroke formation until it is too late. 
 Figure 1 Two types of aneurysms classified by shape (bafound.org) 
2 
 
Various genetic and lifestyle factors can increase the likelihood of stroke. Age is a significant 
factor in stroke susceptibility (66% of stroke patients are over 65), but strokes do occur in people 
of all ages.1 Lifestyles and  resulting comorbidities can also affect stroke susceptibility, with high 
blood pressure, high cholesterol, smoking, obesity, and diabetes all increasing the likelihood of 
stroke.1 Even though these relationships are well-established, the actual detection of the 
aneurysms that precede hemorrhagic stroke is a difficult proposition. Identification of aneurysms 
requires an angiogram, a medical imaging technique performed by injecting a radiopaque 
contrast agent into the bloodstream so that the blood vessel anatomy can be observed with a 
fluoroscope or X-ray. This surgery is expensive, time-consuming, and highly specialized; thus it 
is not performed as a routine diagnostic procedure. Most aneurysms are discovered when 
performing other procedures and are then treated. 
A saccular aneurysm can be modeled as a simple spherical pressure vessel as shown in Figure 
2.4 In this model, stress σ (Newtons/meter2) in the aneurysm wall is proportional to pressure p 
(Pascal or Newton/meter2), radius r (meter), and inversely proportional to wall thickness t 
(meters) via Equation (1).4 While neither the blood pressure nor maximum vessel wall stress 
change drastically or significantly in the human body, the radius of the aneurysm does increase 
over time. According to Equation (1), as either pressure or radius increase (or as the wall thins 
out), the wall stress must increase.4 When the radius increases past the aneurysm wall’s max 
stress, the vessel will burst, causing hemorrhagic stroke. To prevent this, the maximum wall 
stress capabilities could be increased, the pressure and radius can be decreased, or the wall 
thickness can be increased. Since increasing the aneurysm wall’s natural maximum stress is an 
impossible task, steps are taken to modify the blood pressure and radius of the aneurysm. Initial 
passive techniques include medication, reduced exercise, and dietary restrictions to lower blood 
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pressure. However, surgical intervention is often needed to prevent further aneurysm 
development. A variety of devices and products have been developed to reduce pressure in the 
aneurysm or shrink the total wall exposed to the endovascular blood pressure in order to prevent 
aneurysm rupture. 
  
Current Neurointerventional Treatments 
Metal Embolic Coils 
The current gold standard in minimally-invasive aneurysm treatment is the use of metal embolic 
coils. These coils are pushed straight through a microcatheter into the aneurysm. The coils then 
curl as they are exposed beyond the tip of the microcatheter. Once inside the aneurysm, they ball 
up and the surgeon fills it with as many coils as possible as shown in Figure 3.5 This disrupts 
    𝜎 =  
𝑝𝑟
2𝑡
 
(1) 
Figure 2 A spherical pressure vessel and its associated size, 
pressure, and stress labels (unl.edu). 
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blood flow and promotes clotting inside the aneurysm so that it can heal rather than continue to 
expand. 
     
Metal coils do have some significant disadvantages. For one, metal coils are unable to fill more 
than 30% of aneurysm volume. In addition, even the softest metal coils are orders of magnitude 
stiffer than the surrounding tissue, leading to stress mismatches and uneven force transfer at the 
tissue-coil interface. This can lead to recanalization and then further expansion of the aneurysms. 
Recanalization increase is related to aneurysm dome and neck size (Figure 4 and Table 1), with 
15-35% recanalization in all medium aneurysms, and 25-50% in medium wide-necked 
aneurysms; large and giant wide-necked aneurysms are even more difficult options for coil 
treatment, with 35-70% recanalization rates.6–17 
Figure 3 Diagram showing the process of filling an intracranial 
aneurysm with metal coils (hopkinsmedicine.org) 
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Table 1 Aneurysm Dimensional Classifications 
Aneurysm Size Classification Medium Large Giant 
Dome Height (mm) 5-15 16-25 25+ 
Neck Size Classification Small Medium Wide 
Dome-Neck Ratio18 >2:1 2:1 to 1.33:1 <1.33:1 
 
Another limiting factor of metal embolic coils is cost. One very common product, Stryker 
Neurovascular’s Target 360 platinum-tungsten coil, costs $700-$1,500 per coil. Assuming an 
average use of 8-10 coils per aneurysm, the total cost of embolization agent per procedure is 
approximately $10,000. For larger, aneurysms, this number can balloon to over $100,000.19,20 
This is only the cost of the embolic agent, meaning that the total surgical cost is much greater.   
Liquid Embolics 
Liquid embolics, sometimes called “liquid coils,” have been developed more recently to address 
some of the primary concerns with metal coils: recanalization, difficulty filling larger aneurysms, 
Figure 4 Saccular aneurysm dimensional schematic 
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and cost. These products consist of some sort of liquid that can be injected through a 
microcatheter and cure into a solid to fill the aneurysm (Figure 5). These devices are 
advantageous in that they can conform to any shape, including wider-necked aneurysms that are 
difficult to treat with coils. In addition, liquid embolics distinguish themselves from coils and 
other products in that they can completely fill aneurysms without any dead volume, a condition 
that often leads to long-term complications and repair failure.7,8,10,12,13,15,16 They can be sold as a 
single application capable of treating any aneurysm size, which drastically reduces both cost and 
procedure time. They also have the advantage that they can be used in conjunction with the 
current coil standard to fill gaps left between coils to minimize the potential for recanalization. 
     
Only one liquid embolic has become popular in clinical use: Onyx (Onyx HD-500®) by 
Medtronic. It is composed of ethylene co-vinyl alcohol (EVOH) dissolved in dimethyl sulfoxide 
(DMSO). After Onyx is injected, the DMSO solvent dissipates into the bloodstream. In order to 
reduce cytotoxicity and vasospasm caused by acute DMSO exposure, Onyx must be injected 
Figure 5 A liquid embolic being injected into an aneurysm via 
microcatheter with a balloon occluding the neck to prevent downstream 
migration of the embolic agent. 
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slowly, which leads to long procedures and additional complications.21–30 In addition, Onyx must 
be used with specific catheters that are chemically compatible with its components. The 
combination of these factors has prevented Onyx from becoming clinically standard. 
Other Treatment Options 
The final category of endovascular surgical aneurysm treatments consists of flow-modification 
devices, namely flow diverters and flow disruptors (Figure 6).31 Flow diverters, such as the 
Pipeline Embolization Device (PED) (Medtronic), promote flow through the blood vessel rather 
than the aneurysm. Graft-stents, which consist of flexible fabric or sheet of material surrounding 
a stent, can also be used to direct blood flow.32 Flow disruptors, such as the Woven EndoBridge 
(WEB) device (Sequent Medical), fill the aneurysm to minimize flow inside it. Unfortunately, 
both of these devices are metal and therefore have limited biocompatibility. In addition, they are 
unable to conform to irregular anatomies and cannot effectively promote healing in medium- and 
wide-neck aneurysms.33–37 
 
Figure 6 Pipeline Flow Diverter (left) and WEB Flow Disruptor (right) (Jiang et. al 2016) 
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PPODA-QT – a Novel Liquid Embolic Material 
One material, PPODA-QT, has already shown promise as a new type of liquid embolic that can 
be used to treat aneurysms. It has been developed in collaboration between Arizona State 
University (ASU), Northern Arizona University (NAU), and Aneuvas Technologies (ATI, 
Flagstaff, Arizona). 
Chemistry 
PPODA-QT is a 3 part polymer that can be made quickly and cheaply, and is also compatible 
with all existing catheter technologies. It consists of polypropylene glycol (PPODA), 
pentaerythritol tetrakis (3-mercapto-propionate) (QT), which crosslink independently, without 
the need for additional agents (Figure 7).38 A basic aqueous activator accelerates this process 
from hours to under 5 minutes, making this reaction amenable to endovascular surgeries, where 
longer balloon protection times have been linked to ichemia.25,39 This solution is made of 
iothalamate meglumine (Conray® 60) brought to 11.00pH by 5.0N NaOH. Conray® is used 
because it is radiopaque, meaning it is visible during the procedure under fluoroscopic imaging. 
This enables it to be used in minimally-invasive endovascular procedures.  
Previous Studies 
PPODA-QT has already been used in in vivo and in vitro studies. Surface analysis of PPODA-
QT has been performed (Figure 8), but in-depth particulate characterization has not yet been 
performed.40 It has been found to be non-adhesive (to the surrounding tissue), self-aggregating, 
biocompatible, and allow blood vessel healing in canine models (Figure 9).41 One of the goals of 
the BDL at NAU is to use a new rabbit model that uses a less traumatic model creation surgery 
to further demonstrate PPODA-QT’s biocompatibility.  
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Figure 7 (A) PPODA (Mw≈900), (B) QT (Mw≈488), (C) Michael-type addition reaction mechanism 
(Brennecka et. al 2012) 
Figure 8 PPODA-QT visualized by SEM at 418x (McLemore et. al 2009) 
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 Risks 
While all medical procedures involve risks, endovascular neurosurgery is exceptionally 
hazardous due to surgical proximity to essential tissues. In order to minimize the chance of harm 
to patients, a number of standards have been developed to ensure devices are adequately safe for 
use. These include requirements that devices will conform to stiffness, foreign, and visibility 
standards so that they can be used by different surgeons with the same results. In the case of 
liquid embolics such as PPODA-QT, potential downstream migration of the device during and 
after curing is a major concern and must be understood completely. The United States 
Pharmacopia (USP) is a collection of standards and drug information that is used regulate 
medical devices. 
 
Figure 9 PPODA-QT (A–C), Coil and PPODA-QT (D–F), and Coil Only (G–I) explanted canine aneurysms. The 
Coil Only group shows the least amount of tissue growth and healing (Brennecka et. al 2013) 
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USP <788> 
The USP <788> Standard focuses on the safety of injectable liquids in terms of their embolic 
risk. It sets limits on the number of particles of different sizes released during an injection of a 
given material in order to minimize downstream embolisms. It outlines two methods for 
analyzing the number of particles released: in-line particle counting and filter-based microscopic 
analysis. This project focuses on the latter. Particles smaller than 10µm in diameter, are 
considered too small to be of concern, those from 10-25µm are of moderate concern, and those 
≥25µm are of high concern (Table 2).42  
Table 2 USP <788> Requirements 
USP <788> 
Particulate Matter in Injections 
Particle Size Allowable Particles Per Injection 
≤10µm NA 
≥10µm ≤3000 
≥25µm ≤300 
 
Research Questions, Hypotheses, and Aims 
Within the context embolic risk, two questions must be answered when developing injectable 
biomaterials (such as PPODA-QT) for medical use: 
Research Question 1 – Can the liquid embolic meet the USP <788> requirements of 
particulate matter released during injection? 
Research Question 2 – Regardless of conformation to USP <788>, can the liquid embolic 
be successfully used to treat aneurysms without downstream embolic consequences? 
To answer these questions, the following hypotheses are proposed: 
12 
 
Hypothesis 1 – An in vitro system that mimics human physiological and anatomical 
conditions can be built to test liquid embolic conformation to the USP <788> 
Hypothesis 2 – An in vivo aneurysm model can be developed to evaluate liquid embolic 
without observed negative embolic effects 
The subsequent chapters explore the three specific aims that were used to confirm the 
hypotheses. They are: 
Aim 1 – Develop an in vitro model that mimics human physiological and anatomical 
conditions 
Aim 2 – Use the aforementioned in vitro model and different microscopy techniques to 
characterize the shape and number of liquid embolic particles released during 
aneurysm embolization 
Aim 3 – Develop an in vivo rabbit aneurysm model that can eventually be used to 
evaluate liquid embolic efficacy and safety 
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CHAPTER 2 
AIM 1 - IN VITRO MODEL DEVELOPMENT 
Background 
Before their use in humans, medical devices must be tested in a variety of scenarios to prove that 
they will be safe. A variety of models can be used to simulate different physiological contditions. 
These can be classified into two types: in vivo and in vitro models. In vivo models are living 
organisms. Common in vivo models for neuroendovascular procedures are pigs and dogs.6,18 
They can be used to mimic physical characteristics of the eventual human patient, such as the 
Reference papers with both size and shape of a bone implant, or they can be used to assess 
biologic compatibility, such as the effectiveness of drugs in disrupting physiological processes. 
In vitro models take place outside of the organism in both biological and non-biological systems. 
These models can be used to assess material degradation, device mechanical properties, or other 
parameters. In vivo and in vitro models are often used in conjunction to fully evaluate the safety 
and efficacy of devices. 
The goal of this section of the project is to develop an in vitro model that can accurately mimic 
the human neurovascular system in various disease states. This will allow for the testing of 
devices in this simulated condition so that they can be evaluated before human and animal use. 
The development of this in vitro model is Aim 1 in the pursuit of answering Hypothesis 1: 
Hypothesis 1 – An in vitro system that mimics human physiological and anatomical 
conditions can be built to test liquid embolic conformation to the USP <788>.  
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Aim 1 – Develop an in vitro model that mimics human physiological and anatomical 
conditions. 
In Vitro Model System Key Requirements 
Using anatomical and physiological literature review of neuroendovascular systems as well as 
basic ease-of-use and device design constraints, the following requirements were identified: 
▪ Body Temperature 
▪ Physiological Pressures 
▪ Physiological Blood Flow 
▪ Physiological Fluid Viscosity 
▪ Relevant Aneurysm Anatomy 
▪ Accessible via Endovascular Techniques 
▪ Accommodates USP <788>  
The specifications associated with each of these requirements are tabulated in Table 3. 
Table 3 Specifications for the in vitro model 
In Vitro Model Specifications 
Fluid Temperature 37±3°C 
Pulsatile Pressure Mean 100mmHg43 
Flow Rate 100-250mL/min43 
Fluid Viscosity .003-0.004 Pa·s 44 
Aneurysm Size Medium to Giant18,45,46 
Aneurysm Neck Size Small to Large18,45,46 
Endovascular Technique Accessibility Visible and Fluoroscopically Transparent 
Catheter Accessibility Access Port with Hemostatic Valve 
Accommodates USP <788> Downstream Filters to Capture Particles >10μm 
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Materials, Sensing, and Particle Capture 
Each physiological parameter must be monitored with appropriate sensors to ensure that it meets 
the conditions found in the human body. The build and sensors are outlined here: 
Fluid 
The blood was simulated with DI water, but other fluids that would mimic other parameters such 
as viscosity can be substituted into the model. For initial testing, water was sufficient to confirm 
the model could mimic flow rates, pressures, and temperatures during a procedure. All 
components of the model were connected with silicone tubing. 
Pressure Transducers (PT) 
Utah Medical DPT-100 pressure transducers were identified as ideal candidates for this project 
(Figure 11).47 They have a documented connection schematic so that they can be incorporated 
into various electrical designs. A full specification table is shown in APPENDIX A. They 
consist of a four inputs and outputs: ground, +5V power, PT+ Out, and PT- Out. This signal was 
amplified with an LM741CN operational amplifier (Op-amp) with input and feedback resistors 
of 220Ω and 10kΩ, respectively, in an inverting configuration, giving a gain of -45 (schematic in 
APPENDIX A) was observed to be sufficient to amplify for the data acquisition system (DAQ). 
Figure 10 A schematic of the in vitro flow loop complete with all the necessary physical components. 
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Thermocouples (TC) 
K-type (nickel-chromium/nickel-alumel) thermocouples were chosen for their ubiquity and 
simplicity, as well as their ability to operate over large temperature ranges (Figure 12).48 They 
operate on the principle of unequal electrical conductivity, which generates a miniscule potential 
across the junction of the two metals. Because the voltage is so small, the signal had to be 
amplified by 2 sequential Op-amps in the same configuration as the circuit outlined above 
(APPENDIX A).  
Flow Meters (FM)  
An Omega FTB-421 low flow plastic turbine was chosen for this model because it was capable 
of monitoring a large range of flow rates under 2.5L/min, well above the necessary range 
(Figure 13 and APPENDIX A).49 The output square wave frequency varies as a linear function 
of flow rate, so sampling frequency was chosen to obey the Nyquist frequency, in order to avoid 
aliasing. In addition, pressure changes due to the pulsatile nature of the pump mean that sample 
Figure 11 Utah Medical DPT-100 Pressure 
Transducer with accessories (utahmed.com) Figure 12 Example of a K-type wire thermocouple (thermocoupleinfo.com) 
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times must be very short to avoid frequency change issues that would create averaging concerns 
(Figure 14). When the sampling frequency is increased to 1kHz and the sampling time dropped 
to 0.1 seconds (100 cycles), a clear linear trend can be calibrated (Figure 15). The flow meter is 
fed with a +12V input and a 10kΩ pull-up resistor, and then the output voltage is split between 
two 100kΩ resistors (APPENDIX A). Its operating range is 100-2500mL/min, covering the 
entire range of the chosen neurovasculature.43 
   
 
Figure 13 Omega FTB-421 Pressure 
Transducer. Flow goes through the clear part at 
the top, and the output signal comes from the 
black opening in the bottom (omega.com) 
Figure 14 A plot showing the linear relationship between flow rate and 
digital frequency 
Figure 15 Output showing the change in flow meter digital frequency over the course of 0.75 
seconds. The flow meter can operate on a range from 100-2500mL/min. 
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Signal Amplification Box 
In order to house all of the amplification circuits, a custom box was design in SolidWorks and 
3D-printed out of polylactic acid (PLA) plastic at the Cline Library MakerLab on a 
MakerBotReplicator (5th Gen). The circuits described above and detailed in APPENDIX A were 
housed inside this box (Figure 16). It is capable of amplifying 4 pressure transducers, 2 
thermocouples, and 2 flow meters. This box is powered by an Agilent E3630A power supply set 
to outputs of +/-12V (op-amp power and FM signal), +5V (PT power), 0V (ground). These 
signals output to a National Instruments USB-6009 DAQ, which is connected to the computer. 
 
Pump 
A Stenner 170DM5 infusion pump was chosen for its robustness, tunability, and ability to run for 
long periods of time. It can pump at rates of 1-450mL/min, and the multiple adjustable pumping 
heads allow the user to approximate a physiologically-relevant cyclical pattern (Figure 17).50 
Figure 16 An overview of the Signal Amplification Box 
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Immediately distal to the pump, a 10x2.5” cartridge filter was installed with a polypropylene 
1μm filter to ensure that the fluid being delivered to the model is clean. Because the water is pre-
filtered, the downstream particle capture device will only be capturing particles generated during 
the procedure from the embolic device and delivery tools, rather than debris from the reservoir, 
pump, and other sources. 
 
Particle Capture Filter 
Next, a system to capture downstream particles needed to be designed. A Sterlitech 25mm 
polypropylene filter holder was integrated into the flow so that any 25mm filter membranes 
could be used (Figure 18).51 Filter membranes were chosen because they can easily be analyzed 
via microscopy. Millipore Sigma Isopore 25mm filter membranes were used. After 
experimenting with pore sizes ranging from 0.4-8.0μm, 5.0μm pore membranes (TMTP02500) 
were chosen because they allow for significant image analysis differentiation between the pores 
and the 10+μm particles mandated by USP <788> while still enabling physiologically-relevant 
Figure 17 Stenner 170DM5 Infusion Pump (lockewell.com) 
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flow rates of up to 1250mL/min (Figure 18).52 Physiological conditions in the human vessels are 
113-367mL/min (internal/external carotid and vertebral arteries for healthy patients) and 
pressures  are 78-149mmHg (internal carotid for elderly patients).43,53 
 
Anatomical Model and Catheter Access 
In order to test endovascular devices accurately in vitro, a model had to be developed. This 
model was created for surgical access simplicity and accurate aneurysm neck sizes and volumes, 
rather than full anatomical accuracy. This makes it an effective model for rapid testing of 
aneurysm treatments. The two-part model was created with a cast polymer resin and plastic core. 
A core was designed in SolidWorks and 3D-printed in PLA. It meets the dimensions of various 
cerebral blood vessels (internal carotid – ICA, anterior communicator – ACA, middle cerebral – 
MCA) as shown in Figure 19, with aneurysm of sizes (height x width x neck) of 12x12x6mm 
(medium size, medium neck), 19x15x8mm (large size, small neck), and 10x8x4mm (medium 
size, small neck), respectively. The simplified model has an aneurysm of 10x8x4mm (medium 
size, small neck), which are incompletely occluded long-term in 21% of cases.7 These models 
Figure 18 Sterlitech 25mm filter holder (L) and an example close-up of pores on an EMD Millipore Sigma Filter 
Membrane (R) (emdmillipore.com) 
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can be modified to meet the sizes and shapes of various aneurysm distinctions as outlined in 
CHAPTER 1, enabling the model to be used for a wide variety of disease states. The core ends 
were capped with silicone tubing that is permanently left in the model. The model itself was 
made of Smooth-On Clear FlexTM 50, a clear, soft urethane resin.54 This material was chosen not 
for its specific stiffness or trackability properties (it is stiffer than native vasculature), but 
because it is clear both optically and fluoroscopically, which makes the model more user-friendly 
than opaque materials. It was mixed and put under vacuum to remove bubbles. A base was 
poured into a mold and allowed to cure for two hours. Then the core was placed on top and the 
mold was filled halfway up the core with another layer of Clear Flex and allowed to cure 
overnight. The next day, the mold was completely filled and allowed to cure overnight. The next 
day, the two halves were split so the core could be removed. Then connectors were inserted into 
the model to connect it to the flow loop. Multiple model shapes and sizes were used over the 
course of this project (Figure 19). 
 
Figure 19 Example CAD drawing of the model core (L), actual model with three aneurysms (C), simplified model with only one 
aneurysm and no branching (R). 
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Digital In-Line Holography 
As an alternative to filter-based particle counting, an in-line holography system was designed to 
be added if desired. This non-invasive system can be added where the inline filters currently are 
positioned. The complicated system of filter insertion, removal, and analysis is susceptible to 
contamination, clogging, and damage, and therefore can be greatly simplified by using 
holography. The system consists of a Helium-Neon laser, which passes through a 40x objective, 
25μm spatial filter, and 26mm diameter x 106mm focal length lens (Edmund Optics 32-246) to 
focus and bring it to the correct size. It then passes through the flowing sample and onto a 
CMOS camera (Basler Ace acA2440-35um) (Figure 20). Then the image can be analyzed to 
count the particles present, as well as their shape and internal structure at any focus depth in the 
sample.55 Furthermore, the holography setup can count particles as small as 1μm, drastically 
increasing the resolution of the counting system. While more expensive to set up, it has minimal 
operating costs and doesn’t require consumables such new filters. In addition, the analysis can be 
done in real-time and without affecting any of the physiological parameters essential to the flow 
loop. It can be used for both acute and long-term procedures with equal ease, offering a drastic 
improvement over the filter technique. 
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Fluoroscopy 
This system was designed to be used with endovascular imaging techniques to make it a realistic 
model. In endovascular surgery, a fluoroscope is used for visualization. A fluoroscope 
continuously emits and collects X-rays that are passed through the surgical site. These X-rays are 
absorbed preferentially by different materials. Materials that are dense (both anatomically and 
molecularly) absorb the X-rays. Less dense materials allow the X-rays to pass more easily. 
Contrast media, such as Conray® outlined in CHAPTER 1, appears dark on the fluoroscopy 
screen. Contrast is used to illuminate the blood vessels and help endovascular surgeons follow 
them to surgical sites. Figure 21 shows the lab’s Philips BV Pulsera Fluroscope and an image 
taken of the simple anatomic model from Figure 21 (R).56 
HeNe Laser 
40x Objective 
Lens Camera 
Sample Spatial Filter 
Figure 20 Schematic of the in-line digital holography setup (top), and a photo of the actual setup (bottom) 
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LabVIEW Interface 
A National Instruments (NI) virtual instrument (VI) was developed in order to monitor the flow 
loop and ensure that all physiological parameters are met. The signals are read from the NI USB-
Figure 21 Philips BV Pulsera (L) (labx.com) and an image of the simple aneurysm model filled with contrast. The model is held 
together with steel clamps that appear black (R) 
Figure 22 Total in vitro flow loop physical setup 
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6009 DAQ, converted into arrays, and then analyzed. The user selects a specific sampling 
frequency and number of samples to export. For example, a sampling frequency of 1000Hz and 
100 samples would output an array of 100 data points every 0.1 seconds. This data is then 
averaged and fed into a calibration structure. Under “Automatic Calibration,” the user selects a 
minimum and maximum value for each sensor and clicks a switch when the sensor is subject to 
that condition. Once two data points have been recorded, a linear fit is computed so that all other 
values can be interpolated. The pressure transducers, thermocouples, and flow meters are 
calibrated with a blood pressure cuff, room and body temperature solutions, and a volumetric 
flask, respectively. The pressures and temperatures were calibrated at ranges of 50-180mmHg 
and 23-37°C, respectively. Due to issues with recording data at a high sampling frequency and 
the necessity of a high frequency to analyze the digital flow meter, flow rates were measured 
manually with a 200mL volumetric flask. The calibration values can then be brought over to the 
“Manual Calibration” setting, where the user can adjust and save the values. The values are also 
averaged for easier real-time visualization and plotted. The data for all sensors can also be 
recorded to a timestamped .csv file for further analysis. Figure 23 shows the front panel of a 
streamlined version of the VI (block diagram can be found in APPENDIX A). 
8 Tests with 0-4500 suspended 10μm polypropylene particles (2 trials at each number)) were 
performed, as well as 3 trials with PPODA-QT (outlined in CHAPTER 3). The particles were 
injected into the aneurysm, and flow was maintained for 20 minutes. “Before” was defined as 
before the injection was performed, and “after” was defined as after the 20 minutes of flow. The 
pressures, flow rates (calculated manually with 200mL volumetric flask), and temperatures (from 
water bath with stir plate thermometer) shown in Table 4 (all data in APPENDIX A) are taken 
before, during, and after this whole process at a frequency of 50Hz and 5 samples read at a time, 
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and results were found to be similar to those found in the literature.43 Proximal refers to the 
pressure gauge at the inlet of the model, and distal refers to the gauge immediately downstream 
from the filter. The data is also summarized by comparing the pressure drop across the filter at 
the beginning and end of the 0 sphere trial (Figure 24), the average pressure drop for all trials 
over the course of the experiment (Figure 24), and the drop in flow rate in all filters over the 
course of all trials (Figure 26). The deviations given for each trial is the difference between the 
mean and the max/min of the oscillating waveform, so it can be thought of as the difference 
between average blood pressure and systolic/diastolic maximum/minimum blood pressures. 
These are plotted as error bars in Figure 24, Figure 25, and Figure 26, which show that pressure 
Figure 23 Simplified version of the Flow Loop Monitor VI that tracks the physiological parameters in the in vitro flow loop 
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remains constant over 20 minutes of flow and the pressure and flow rate drops over 20 minutes 
remain constant for all trials of particulate injections.  
Table 4 Parameters recorded during particle control test. Data was taken before the test and after 20 minutes of flow. 2 trials 
were used for each microsphere injection, and 3 were used for the PPODA-QT tests. 
  
Proximal Pressure 
(mmHg) 
Distal Pressure 
(mmHg) 
  
Trial Time Mean Deviation Mean Deviation 
Flow 
Rate 
(mL/min) 
Temperature 
(°C) 
0 
Spheres 
Before 133 40 22 11 222 
37-40 
After 154 19 29 18 214 
1500 
Spheres 
Before 136 19 29 11 235 
After 152 11 24 3 222 
3000 
Spheres 
Before 136 31 27 12 231 
After 150 44 30 10 222 
4500 
Spheres 
Before 138 50 31 12 235 
After 130 42 18 12 226 
PPODA-
QT 
Before 118 57 26 12 119 
After 125 56 28 14 113 
0
20
40
60
80
100
120
140
160
180
200
0min 20min
P
re
ss
u
re
 (
m
m
H
g)
Pressure Across Filter after 20min of Flow
Proximal
Distal
Figure 24 The pressure on both sides of the filter after injecting DI water containing 0 particles. 
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Discussion 
The in vitro flow loop was built such that surgical scenarios can be mimicked accurately for both 
training purposes as well as device development. With a combinations of the components 
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Figure 25 The pressure change from proximal to distal the filter for all trial configurations. 
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Figure 26 The change in flow rate across each filter for each trial configuration. 
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outlined earlier, all of the design considerations laid out in the In Vitro Model System Key 
Requirements section have been met. Physiologically relevant pressures, temperatures, and flow 
rates have been achieved with 5.0μm filters, which can be removed for later analysis counting. 
The other physical requirements such as size and radiopacity have been met, and this model can 
be used for accurate surgical practice. Other aneurysm shapes and sizes can be made to span the 
ranges of potential disease states.  
Over the course of 20 minute non-particulate trials, no significant difference was observed in 
pressures, indicating that the system is stable and sufficiently contamination-free for reliable use 
with the filters without clogging. In addition, even with 4500 injected 10µm spheres (well above 
the USP <788> standard), the system is still stable. This indicates that this system can be used 
for particulate analysis and understanding even beyond the scope of human use. Furthermore, 
flow rate drops from the beginning of the test stayed statistically constant for all of these levels 
of particulates. Furthermore, no difference in pressure or flow rate drop between PPODA-QT 
and the microspheres was observed, indicating that it may not pose a human particulation hazard. 
This will be explored further in CHAPTER 3. 
As the digital flow meter presented problems related to sampling rate and measurement accuracy 
necessitating manual measurement during all tests, a different flow meter should be acquired. An 
analog flow meter could be incorporated into the system with an op-amp system similar to the 
pressure transducers and thermocouples. This would enable the BDL to record all data at lower 
sampling rates and keep hands-on work minimal. 
In addition to the flow meter upgrade, a new USB data acquisition system could simplify the 
process. The sampling rate on the USB-6009 system is limited by the number of channels being 
used. By upgrading this system to one containing the common NI 9201 and NI 9213 (National 
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Instruments, Austin, Texas) for pressure transducer/flow meter and thermocouple acquisition, 
respectively, the limited sampling frequency and need for the custom signal amplification 
developed here would be eliminated. This would add to the usability of the system and allow for 
faster design iterations and upgrades. 
The culmination of this work is that the lab now has a documented, modifiable model for testing 
endovascular devices. This will allow the laboratory to further expand laboratory scope, test 
more mechanically-accurate blood vessel mimics, and practice procedures for new and existing 
methods. 
 Aim 1 is now complete, as an in vitro model has been developed that simulates human 
physiological and anatomical conditions. CHAPTER 3 will use this model to develop a method 
for confirming adherence to USP <788> as outlined in Hypothesis 1.  
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CHAPTER 3 
AIM 2 - PARTICLE COUNTING AND CHARACTERIZATION 
Background 
Any medical procedure contains inherent risk. When medical professionals treat a given 
disorder, the aim is to treat it quickly, effectively, and reduce the possibility of causing other 
issues. While some of these hazards may be small, many of the dangers present during 
neuroendovascular procedures are exceptionally high.  Any mistakes made during neurosurgery 
can have immediate life-changing consequences. Therefore, devices designed for treating neural 
disorders must be designed with the highest standards in mind. In the case of treating cerebral 
aneurysms, these standards guide engineers to design products that minimize the risk for 
aneurysm rupture, accelerate procedure times, and have minimal potential for downstream 
embolism. 
Many of these issues have already been resolved for PPODA-QT and other liquid embolics. As it 
is delivered as a liquid, the risk for aneurysm perforation is negligible in comparison to coils. 
Rupture due to over-pressurization remains a concern if the balloon seal is too tight, but previous 
studies have shown successful embolizations in canine and porcine animal models.6,39 PPODA-
QT can be delivered rapidly to reduce surgical risk, as balloon occlusion time longer than 5 
minutes has been associated with increased complications.6,38 Onyx®, a current liquid embolic 
can only be injected slowly to reduce negative effects of the solvent DMSO, resulting in multiple 
balloon inflation cycles and injections. One study found an average Onyx® procedure time of 95 
minutes, which furthers the risk of surgical complications.25 These effects include vasospasm and 
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cytotoxicity, which can be eliminated with the faster and DMSO-free procedure that PPODA-QT 
provides.6,17,21–24,27,46  
Downstream embolic risks due to particulation from PPODA-QT are currently unknown. The 
focus of this project is to develop methods to test downstream particulation so these methods can 
be applied to PPODA-QT and other materials. To deliver nutrients to different regions of the 
body, arteries taper to arterioles and eventually capillaries. This allows for diffusion and other 
transport processes to act at a sustainable rate. These capillaries often reach diameters as small as 
3μm, meaning that the 6-8μm red blood cells must often fold themselves in order to pass 
through.57,58 These tiny blood vessels are redundant, so neighboring vessels can provide 
sufficient nutrients to feed tissues in the case that some were embolized. However, ischemia 
occurs if enough vessels are blocked that the surrounding tissue is not delivered essential 
nutrients, a process that eventually causes tissue death. USP <788> sets limits on the 
microscopic particles shed during liquid injections so that ischemia risks are lowered.42 In order 
verify that liquid embolics such as PPODA-QT can meet the requirements of USP <788> under 
simulated human conditions, this chapter focuses the developed in vitro model, along with 
multiple imaging techniques, to assess injection particulates for USP <788> compliance in the 
following aim and hypothesis: 
Hypothesis 1 – An in vitro system that mimics human physiological and anatomical 
conditions can be built to test liquid embolic conformation to the USP <788> 
Aim 2 – Use the aforementioned in vitro model and different microscopy techniques to 
characterize the shape and number of liquid embolic particles released during 
aneurysm embolization 
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Methods 
Two distinct materials were compared in this study: PPODA-QT cured in solution as well as a 
10.0μm polypropylene sphere particle counting standard. PPODA-QT was analyzed via SEM, 
and both were used in filter analysis via DIC microscopy. An automated counting program was 
developed for this analysis. Finally, digital inline holography feasibility was performed with the 
10.0μm sphere standard. 
PPODA-QT Preparation 
PPODA-QT was prepared similarly for all tests. 1.080g of PPODA (average molecular weight 
~800, Sigma-Aldrich, St. Louis, MO) was mixed with 0.330g of QT (Sigma-Aldrich, St. Louis, 
MO) via two 3mL polypropylene syringes connected with two female-female luers and one 
male-male luer to increase mixing (Figure 27). These are mixed via a series of 30 strokes, and 
each stroke is completed in under 1 second. Then 0.37mL of Conray-60® contrast agent 
(Villepinte, France) diluted to 11.0pH with NaOH, was added and the entire solution was mixed 
for 1 minute at the rate above. It was then injected through a needle into a liquid solution, or 
through a mock catheter made of 0.025” inner diameter polyimide tubing attached to 18 gauge 
EFD dispenser tips (Nordson Medical, East Providence RI) into the aneurysm model. 
 
Figure 27 Syringe-Fitting configuration for PPODA-QT mixing 
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Scanning Electron Microscopy 
Scanning Electron Microscopy (SEM) was used to perform initial tests and characterization. As 
SEM only highlights surface features and is a delicate instrument requiring specific coatings and 
other preparation techniques, it was only used for visual characterizations of PPODA-QT particle 
visualization and counting for USP <788>. Samples of PPODA-QT were prepared as outlined 
above and injected into beakers filled with water or saline. They were then allowed to cure and 
the aqueous solution was filtered through EMD Millipore 0.4μm polycarbonate filters. Filters 
were dried, mounted to aluminum studs, and then coated with Gold-Palladium for SEM analysis. 
USP <788> 
As outlined in CHAPTER 1, USP <788> governs the allowable particles shed during injection. 
Table 2 details the requirements laid out by the standard. In addition to those outlined above, a 
requirement of test cleanliness is laid out: no more than 20 particles ≥10μm or 5 particles ≥25μm 
are allowed. This cleanliness can be accomplished by using a particulate hood, ultrapure water, 
and other precautions. As the BDL does not currently have all of these capabilities, samples were 
covered and protected from dust during all storage. Samples of 10.0μm polystyrene spheres 
(EZY-CALTM Particle Size Standards, Thermo Scientific) were diluted to varying concentrations 
between 0-4500 parts/mL with ultrapure water in a laminar flow hood. All items were washed 
with soap, isopropyl alcohol, and then rinsed in a sonicator filled with ultrapure water.  
In-Line Digital Holography 
A digital holography setup (outlined in CHAPTER 2) was designed to image particles flowing 
downstream of the injection site in the in vitro model. A Helium-Neon laser (HeNe) (633nm 
wavelength) was passed through a 40x objective and 25μm spacial filter to improve the beam 
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quality. A 26mm diameter x 106mm focal length lens collected the diverging light and 
collimated it to pass through the sample and on to the CMOS camera. The sample consisted of 
water containing 2000 particles/mL of the 10.0μm standard clamped between two glass slides. 
Differential Interference Contrast Microscopy 
Optical microscopy was also used because it is faster and requires less up-front cost than either 
of the methods shown above. 10.0μm particles were injected into a mock aneurysm and flow was 
maintained for 20 minutes. PPODA-QT was injected into a mock aneurysm under Fogarty 
balloon (Edwards Lifesciences, Irvine, CA) protection and allowed to cure for 10min. The 
balloon was then deflated but remained in place for another 20 minutes. 5.0μm polycarbonate 
filters were used to capture particles downstream during this time. They were then placed on 
glass slides and imaged using a Leica DMi8 confocal microscope at the Imaging and Histology 
Core Facility at NAU. Images were taken using DIC microscopy, a special type of microscopy 
with which augments slight changes in refractive index of transparent samples. This technique 
hightlights relatively transparent objects such as the bead standard and PPODA-QT particles on 
the polycarbonate filters (Figure 29). The edges of the filter were identified and the microscope 
was set to automatically take and stitch together images across a square on the x-y plane that 
covered the entire filter. For a 25mm diameter filter, this is a total of 600-700 images at 10x 
magnification, equating to a square with roughly 25-26 images per side. It also did this at 
multiple z heights to focus across small variations on the filter surface (Figure 28).59  Any 
images that contained the edge of the filter or outside were discarded during analysis to reduce 
edge effects such as the forceps scratches on the top of the DIC image in Figure 29. 
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Counting Methods 
The particles were analyzed via a combination of ImageJ (National Institutes of Health, 
Bethesda, MD) and MATLAB (MathWorks, Natick, MA) software. A MATLAB program was 
used to open the images in ImageJ. The user then set the intensity threshold to filter aberrations 
in the image. The 5.0μm pores were used for reference for size. Then the MATLAB program 
automatically subtracted all of the images at different focus levels for a given x-y position (one 
Figure 28 Example of the x-y grid of pictures taken (L), and an example of a sphere taken at various focus depths to illustrate the 
use of a z stack (R) (Northwestern University) 
Figure 29 Example of a filter analyzed under normal bright field (BF) light microscopy (L) and Differential Interference 
(DIC) microscopy (R) 
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z-stack). This reduces glare and other intensity issues and makes particles on the surface of the 
filter even more distinct. ImageJ was then set to detect and count any image larger than 79μm2, 
which would ignore distinct pores but identify any particles larger than 10μm in diameter. These 
particles were then counted for all images. They are outputted and sorted by area, semi-major, 
and semi-minor diameters. A flow chart for this process is shown in Figure 30, and the code for 
this program is shown in APPENDIX B. 
 
Results 
USP <788> 
All methods used to characterize the system and PPODA-QT for USP <788> are outlined in their 
respective sections below. 
Scanning Electron Microscopy 
Images of PPODA-QT showed distinct morphology depending on how the particles were 
generated. Some pieces of PPODA-QT were spherical, whereas others had jagged edges (Figure 
31). These shapes can be used to categorize the particles. SEM was not used to characterize 
PPODA-QT for USP <788>. 
Figure 30 Flow chart illustrating the process of the coupled Matlab and ImageJ automated particle counting analysis. 
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Figure 32 shows the smooth surface texture of PPODA-QT that was injected through 
microcatheters into DI water and allowed to cure in situ. The smooth surface features support the 
categorization discussed above and shown in Figure 29.  
 
Figure 31 SEM image taken of various PPODA-QT morphologies. On the left is a 500x image with multiple particles of PPODA-
QT. This sample was generated with little concern for contamination (such as the bubble and large flake on the left), but still 
shows multiple types of PPODA-QT shapes. In the center is a ~10μm PPODA-QT sphere, and smaller PPODA-QT spheres are 
scattered throughout the image. In the top right, expanded in the image on the right, are different small particles, including 
spherical and jagged PPODA-QT. 
Figure 32 A 418x image of the surface of PPODA-QT when formed in DI water. 
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Digital Holography 
Initial feasibility of the inline digital holography counting method was proven. Images of the 
sample showing a strong diffraction pattern due to either the 10.0μm particles or microscopic 
surface contamination. Further refinements are necessary for full holographic resolution, but 
proof of concept images are shown in Figure 33. 
 
Differential Interference Contrast Microscopy 
DIC microscopy was the method used to count particles for USP <788> compliance. Figure 34 
shows the steps in the counting process. a) shows the original image used for processing at a 
given x-y location. The entire 8 image z-stack (10.0μm spacing) at this location was analyzed via 
MATLAB and ImageJ, and the minimum intensity at each pixel was used to create image b). 
Then it was converted to black and white and the intensity threshold was increased so that many 
of the pores would be removed, as seen in c). Finally, c) was analyzed so that the particles above 
79μm2 (10μm diameter) were identified in d), and the output particle sizes are shown in the table. 
Figure 33 Images showing the edges of air bubbles as well as small particles and their associated diffraction patterns (L) as well 
as an image showing the base diffraction pattern of the CMOS camera detector cover (R) 
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This process must be set once for every image, and then it will automatically apply the same 
process to the rest of the images in the sample. 
 
This was repeated for 8 samples to generate a calibration curve ranging from 0 to 4500 input 
10.0μm beads. The number of particles counted by the automated method was orders of 
magnitude from the expected value, as well as inconsistent between tests. Trial 2 with 3000 
particles was ignored as an outlier (Table 5 and Figure 35). 
Figure 34 The various stages of particle counting via DIC microscopy, MATLAB, and ImageJ. a) shows the most in focus 
image in a given z-stack. b) shows the same location, but with each pixel corresponding to the minimum intensity across 
the 5 image z-stack (10.0μm spacing). c) shows this image once it has been converted to black and white and the intensity 
threshold was increased to remove many of the pores and small objects. d) shows the 2 particles detected, as well as the 
output of their area and major and minor diameter. 
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After this, PPODA-QT was injected into an aneurysm in the model as described in the methods 
above. The aneurysm dimensions of 10 x 8 x 4mm (H x W x Neck), making it a small, small-
necked aneurysm with a volume of ~0.35mL. Each sample released 1 large (~1mm) particle, and 
similarly-sized particles stuck to the catheter and balloon was observed in all 3 samples (Figure 
36). This has not been observed by the BDL animal models or in models using new, FDA 
approved neuroendovascular balloons and microcatheters, so future tests should incorpo rate 
those devices instead of the substitutes used here. The automated particle counting is shown in 
Table 5 and Figure 35. 
 
Table 5 The number of injected sphere standards and PPODA-QT injected into the model and the number of particles counted by 
the automated counting program. The 3000 Sphere Trial 2 was ignored as an outlier because it at least one orders of magnitude 
different than the other trials. More explanation below. 
Material Trial 10-25μm Particles >25 μm Particles 
0 Spheres 
1 1 0 
2 5 3 
1500 Spheres 
1 64 2 
2 85 3 
3000 Spheres 
1 4 6 
2* 670* 162* 
4500 Spheres 
1 10 0 
2 13 4 
PPODA-QT 
1 11 2 
2 16 7 
3 13 3 
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Figure 35 Particles counted by the automated particle counting method vs the number of particles put into the system. 
Figure 36 Image showing a mock catheter with PPODA-QT stuck to the tip (L), the explanted PPODA-QT 
embolic (C), and a 3mL syringe for reference (R) 
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Discussion 
Scanning Electron Microscopy 
SEM has been established as a method for understanding surface features and other particulate 
characterization of liquid embolics such as PPODA-QT. Particles cured as individuals and those 
broken off larger pieces can be distinguished. While it was not explored here, this could 
potentially prove to be a reliable method of determining specifically how PPODA-QT 
particulates over the duration of an injection and in long-term studies. Individual spherical 
polymer particles formed independently are likely the lowest-risk shape from a clinical 
perspective. While they do not form the smallest possible cross-section in a certain direction, 
they are consistent in all directions and therefore the symmetry means that they only pose 
embolic risk in situations with vessels of a smaller diameter. In addition, it appears that 
individual particles can form on the order of single microns (Figure 31) meaning that many of 
the particles shed from this procedure could pose no embolic risk. However, cytotoxic and 
genotoxic risks of these microscopic particles have not been investigated and would be addressed 
during FDA-mandated ISO 10993 testing, which is beyond the scope of this project. 
Digital Holography 
Holography has been established as a completely novel method to image PPODA-QT and other 
liquid embolics. It can be used to gain 3D information regarding the polymer as well as measure 
its particulation characterization. Further analysis will need to be done in order to bring its full 
potential to USP <788> and other particle characterization applications, but this remains a 
promising use of this technology. 
Differential Interference Contrast Microscopy 
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DIC microscopy has been applied to obtain large quantities of data quickly in a form that is 
simple to analyze. Through the development of MATLAB and ImageJ analysis programs, it now 
can be used to rapidly analyze filters used to capture downstream particles. Now that this 
analysis method is set up, it can be used for this and other applications where many pictures must 
be analyzed for particulate or other object detection. 
However, this counting method still needs further development. Particle counts were far from 
expected values, indicating that procedural modifications must be made. This could include 
further validation of input particle quantities, as well as further analysis to find any locations in 
the model where particles could be trapped before they reach the filter. 
Furthermore, the 3000 Sphere Trial 2 had an order of magnitude greater number of particles 
counted than the other trials, including >25μm particles (of which there should be none). Due to 
analysis delays, the image was taken a week after the filter system, and it appears that hundreds 
of contaminating particles were deposited on the filter in this time. This, combined with the fact 
that the particle counts are orders of magnitude larger than any other trials, justifies it being 
removed as an outlier in Figure 35. Notably, the 1 Sphere Trial 1 had the same analysis delay 
but did not show the same level of contamination. This highlights the high variability present in 
the filter method due to handling. 
USP <788> 
Because the counting methods are still under development and more tests must be run to 
determine their accuracy, USP <788> compliance has not yet been established. In addition, 
contamination greater than the requirement of than 20 particles ≥10μm or 5 particles ≥25μm 
remains outstanding. 
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Conclusion 
While the framework for two test methods has been developed, further work must still be done in 
order to bring both the DIC microscopy and inline digital holography to full USP <788> 
compliance. More controls should be run in order to determine whether the test methods 
successfully capture and count all particles put into the system. As discussed earlier, this would 
include using the proper neuroendovascular devices to prevent sticking, as well as potential 
investigations into ways that particles are trapped on surfaces in the flow loop other than the 
filter surface. Steps should be taken to decrease contamination, such as performing the test in a 
laminar flow hood or a cleanroom. Due to a combination of lack of success with DIC 
microscopy analysis as well as the time-intensiveness, invasiveness, and resulting variability of 
the test, future studies should focus on holography as the primary method of particle counting. It 
is non-invasive and live, meaning that it will likely give more accurate, cheaper, and faster 
results.  
Some issues with final particle counting can be attributed to the large amount of filtering and 
automated analysis of the DIC images. Using filters that will generate clearer images, finding 
methods to make surface particles more distinct, and minimizing contamination will make this 
image processing more accurate and precise. If an automated counting process such as that 
presented here is to be used in the future, further steps must be made to ensure the images being 
used more clearly show particles before they are analyzed. 
Once this has been done, PPODA-QT and other materials can be fully tested and assessed for 
USP <788> compliance (Aim 2). An in vitro system that mimics human physiological and 
anatomical conditions has been built, but it is not yet fully ready to test for USP <788> 
46 
 
conformation (Hypothesis 1). Therefore, Hypothesis 1 remains inconclusive until the test 
methods are finalized.
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CHAPTER 4 
AIM 3 - IN VIVO MODEL 
Introduction 
Despite the controls and standards placed upon the in vitro testing of medical devices by various 
regulatory bodies, the final test of practical device safety is often in vivo testing. Depending on 
the specific disease state and method being tested, different models can be used. As discussed in 
CHAPTER 1, previous studies using saccular aneurysms were surgically created in canine 
models (Figure 9). While this model presents an excellent initial feasibility test for the filling 
capabilities of PPODA-QT, it does not provide an accurate picture of the human aneurysm 
position and healing response. The surgical creation, which includes stitching of a jugular vein 
pouch on the carotid artery to form an aneurysm, is limited to side-wall aneurysms of small and 
medium sizes.18 
The leporine (rabbit) elastase model used here improves upon the surgical canine model in that it 
minimizes trauma at the vessel neck, reducing the inherent healing response to the aneurysm 
formation surgery. This means that, in theory, all histological and inflammatory response is due 
to the embolization procedure used to treat the aneurysm, rather than both the aneurysm creation 
and embolization procedures. This model has been growing in popularity and modifications of it 
have been used by many different research groups.30,60–62 
The first step of the procedure is to access the right common carotid (RCC) artery. After access 
is gained, a balloon catheter is inserted to occlude the beginning of the RCC where it branches 
from the right subclavian (RS) artery. The neck can also be occluded with a surgical clip. The 
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occluded RCC is then filled with elastase, which breaks down the elastin present in the blood 
vessel. This weakens it and allows it to expand. Finally, the top of the RCC is tied off so that the 
weakened vessel can slowly grow over the course of a month. Then the aneurysm is ready for 
treatment. This entire process is detailed in Figure 37.63 
When the aneurysm has fully developed, it can be treated with various treatments. This 
procedure is outlined in CHAPTER 1 and below. Afterwards, the animals can be monitored for 
any negative results of the procedure, which may include stroke-like symptoms, right side – left 
side movement inconsistencies, and other neurological defects.  
 
Figure 37 Diagram showing the initial creation procedure and progression of the rabbit elastase aneurysm 
model (Brinjikji et. al 2016). 
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The development of this model is Aim 3 in addressing Hypothesis 2: 
Hypothesis 2 – An in vivo aneurysm model can be developed to evaluate liquid embolic 
without observed negative embolic effects 
Aim 3 – Develop an in vivo rabbit aneurysm model that can eventually be used to 
evaluate liquid embolic efficacy and safety 
Materials and Methods 
The progression of the rabbit model can be divided into three sections: the aneurysm creation 
surgery, embolization procedure, and post-mortem analysis. The three are outlined below:  
Aneurysm Creation Surgery 
New Zealand rabbits were used for this procedure (materials list in APPENDIX C). Multiple 
blood-thinning regimens were adopted in order to prevent clotting of the aneurysm during the 
procedure. At the end of the study, a combination of Plavix (Clipidogrel) (15mg/kg) and aspirin 
(acetylsalicylic acid) (10mg/kg) were administered orally, daily from 3 days before the aneurysm 
creation surgery, and maintained until embolization. They were sedated with 
Ketamine/Xylazine/Acepromazine (60/6/1 mg/kg) and anesthesia was maintained with 
isofluorine (1-1.5% in O2 at ~1 L/min). Sterile technique was used to access and isolate the 
RCC. Access to the vessel was gained with a 24G IV catheter or a modified microcatheter, and 
the RCC branch off of the RS was occluded with a surgical clip. At the end of the study, the 
decision was made to use a 3F Fogarty balloon catheter in a 5F introducer to occlude the RCC 
endovascularly under fluoroscopic guidance for all future animals.  
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A suture was used to seal the vessel around the catheter. 80U of porcine elastase was suspended 
in saline or 9pH PBS and injected into the blood vessel, where it incubated for 20 minutes 
(longer if appropriate if the full volume of elastase did not fit in the vessel or leaked out). The 
clip was then removed, and the RCC was flushed and tied off 2-3cm distal to the RS. The 
surgical site was repaired and the rabbit was monitored for 21 days until the aneurysm 
development was complete. 
Embolization Procedure 
The materials used for this procedure are documented in APPENDIX C. After sedation as 
outlined above, access to the right femoral artery was gained and a 5F introducer was inserted 
into the vessel. Fluoroscopic guidance was used to bring a 5F angiocatheter up to the RS to 
image the aneurysm. After confirmation of the aneurysm size and shape (calculated using 
Equation (2)), a microcatheter was inserted into the aneurysm and a balloon catheter was placed 
over the neck. PPODA-QT was filtered for sterility and then prepared as outlined in CHAPTER 
3. The balloon was inflated with contrast, and the subtraction setting on the fluoroscope was used 
to view the PPODA-QT as it was injected into the aneurysm with a high pressure injection 
catheter. The catheter tip was slowly withdrawn to keep it out of the bolus of the PPODA-QT 
filling the aneurysm. The catheter was left in place until ~5min post-mixing, and the balloon was 
deflated at 6-10min post-mixing. Aneurysm embolization was confirmed via fluoroscopy. All 
surgical tools were removed, the right femoral artery was tied off, and the access site was closed.  
 
    
𝐸𝑙𝑙𝑖𝑝𝑠𝑜𝑖𝑑: 𝑉 =  
𝜋 ∗ 𝑊𝑖𝑑𝑡ℎ ∗ 𝐷𝑒𝑝𝑡ℎ ∗ 𝐻𝑒𝑖𝑔ℎ𝑡
6
 
(𝐷𝑒𝑝𝑡ℎ = 𝑊𝑖𝑑𝑡ℎ 𝑓𝑜𝑟 2𝐷 𝑖𝑚𝑎𝑔𝑒𝑠) 
(2) 
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Necropsy 
Animals were euthanized per the Institutional Animal Care and Use Committee (IACUC) 
approved methods appropriate for rabbits and the American Veterinary Medcial Association 
(AVMA) guidelines or died from surgical complications. The aneurysms were excised, imaged, 
and stored in formalin for histological analysis. If neurological symptoms were observed, a 
craniotomy was performed to look for stroke signs in the brain.  
Results 
Aneurysm creations and embolizations have been performed on a total of 8 animals so far. This 
thesis covers the initial steps to create the model. Future studies by the BDL will improve and 
expand upon the in vivo aneurysm creation and PPODA-QT embolization. 
Aneurysm Creation Surgery 
Aneurysms were created, but they did not accurately represent large saccular aneurysms as 
hoped. Most of them were found to be roughly the same diameter as the original RCC, indicating 
that the elastase digestion did little to nothing to weaken the vessel. Large clots were observed 
occluding the distal section of the vessel, filling nearly half the length of the aneurysm. These 
clots have been observed previously.60 Further studies must be done to improve the aneurysms 
and make the shape more indicative of the natural aneurysm disease state. The new endovascular 
procedure, using a balloon catheter for occlusion, microcatheter for injection, and elastase mixed 
with contrast, shows promise. An angiogram of the area (top) and an example vessel that is 
sealed and filled with radiopaque elastase (bottom) during the elastase incubation is shown in 
Figure 38. 
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Figure 38 The full surgical vessel area (top) and the sealed RCC during the elastase incubation under fluoroscopy (bottom). 
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Embolization Procedure 
Aneurysm sizes of ~0.1mL were filled. These aneurysms were not saccular, however, and they 
had neck sizes roughly equal to the vessel lumen. Complications occurred during injection 
because the radiopacity of PPODA-QT was tuned for visibility in larger aneurysms. Because the 
aneurysmal volume was so small, it was very difficult to view the PPODA-QT filling the 
aneurysm. A close-up view of a “tent-like” aneurysm with the largest width at the neck than 
aneurysm width is shown on the left in Figure 39. This aneurysm is very difficult to treat with 
PPODA-QT as its non-adhesive properties mean it may dislodge from the aneurysm over time 
(Figure 41). This would likely be a contraindication for the use of PPODA-QT and many other 
aneurysm treatment devices. 
 
Necropsy 
Necropsies were performed and the aneurysm site was extracted for analysis. Visual analysis was 
initially performed, and then the sample was stored in formalin for later histological work, which 
is not discussed here. 
Figure 39 Aneurysm filling procedure. Left shows the aneurysm in white. A microcatheter sits inside it, and a balloon filled with 
contrast occludes the neck. Right shows the vessel after the procedure with the aneurysm fully occluded and therefore not visible. 
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Figure 40 Rabbit 9073. The images show the vessel before excision (L) and PPODA-QT visible at the neck of the aneurysm (R) 
Figure 41 Image of PPODA-QT that has been ejected from the aneurysm and would disrupt the RS blood flow. 
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Table 6 Summary of the rabbit embolization surgeries 
Rabbit Embolization Results 
Rabbit ID 
Date of 
Surgery 
Date of 
Embolization 
Date 
Euthanized 
Notes 
9071 10/31/2017 12/4/2017 12/4/2017 
Died of surgical complications 
post-embolization 
9073 10/31/2017 12/7/2017 1/12/2018 PPODA-QT found occluding RS 
9078 10/31/2017 12/5/2017 1/21/2018 
Termed from degloving 
complications, potential 
downstream migration of PPODA-
QT that could also be related to 
trauma during necropsy 
519 12/19/2017 1/9/2018 NA None 
520 1/15/2018 2/7/2018 2/7/2018 
Died of surgical complications 
post-embolization 
524 12/19/2017 1/12/2018 NA 
Died of surgical complications 
post-embolization 
525 1/15/2018 2/6/2018 2/13/2018 
Clot observed on surface of 
PPODA-QT. Will be confirmed via 
histology 
527 12/19/2017 1/8/2018 1/8/2018 
Died of surgical complications 
post-embolization 
 
Discussion 
Inconsistent aneurysm formation was a main cause of concern throughout the model 
development. Rather than saccular aneurysms, the ones created here had a cylindrical shape, 
which would likely be a contraindication for such treatments in human patients, as the potential 
for migration of a liquid embolic is present. Because PPODA-QT is non-adhesive (but self-
adhering), a neck narrower than the total aneurysm width is necessary to prevent migration. Any 
other shape, such as those shown here, would be considered contraindications of PPODA-QT 
unless other procedural or device modifications are made. 
56 
 
The aneurysm creation surgery has undergone multiple iterations. After observing large clots in 
the aneurysm, Plavix and aspirin dosages before and after the procedures were adopted. Due to 
increased skill and shorter procedural times later on, isofluorine anesthesia was abandoned. After 
beginning with external surgical clips, balloons were adopted so that traditional 
neuroendovascular techniques could be continued. Performing this procedure under fluoroscopy 
meant that it was possible to visualize the seal on the RCC branch during elastase (mixed with 
contrast) incubation. Elastase was initially suspended in saline, but 9pH PBS proved to be more 
effective in dissolving it, so that modification has also been made, as well as the addition of 
contrast for fluoroscopic visualization. Finally, a 5F introducer was adopted as the preferred 
access method, which meant that the balloon and injection microcatheter could be inserted and 
removed while maintaining hemostasis. All of these modifications will be essential to further 
studies in the BDL. 
While the in vivo model was successfully embolized in several cases, complications due to poor 
aneurysm formation prevented accurate assessment of PPODA-QT as an effective treatment. 
Because the aneurysms were very small, it was difficult to see PPODA-QT injected into the 
aneurysm. Larger aneurysms or more radiopaque PPODA-QT could remedy this problem. 
However, more radiopaque PPODA-QT would appear too dark in a larger aneurysm more 
relevant to the disease state, where distinguishing between fill volumes would be very difficult.  
In addition, saccular aneurysms are less likely to eject PPODA-QT. Because the aneurysms in 
this study were essentially cylindrical and PPODA-QT is non-adhesive, PPODA-QT could easily 
slide out. In a saccular aneurysm with a larger max diameter than neck size, this would not occur, 
and embolic risks would be minimized. The PPODA-QT would be far better contained. Larger 
aneurysms, which would enable better PPODA-QT visualization, would also reduce the risk of 
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overfilling. A string of PPODA-QT reached into the RS of one animal, and a small hole, likely 
from the injection microcatheter, was observed. This protruding and rough PPODA-QT surface 
could have had negative effects on the blood flow. The ongoing models will be survived up to 
3mo before they are euthanized for analysis. 
Conclusion 
Initial results of embolism with PPODA-QT are promising, but further work must be done to 
ensure the aneurysm model is accurate to truly test PPODA-QT under real world conditions. The 
primary step will be to identify root causes of the lack of aneurysm growth. Different elastase 
compounds, elastase mixtures, longer digestion times, and external application could all be 
investigated to determine how to create better and larger aneurysms. This will likely address 
many of the problems described above. This will also provide further opportunity to optimize the 
process with various catheters, procedural times, and other parts of the process. 
The cylindrical aneurysms described here have the potential to be a new model. Wide-necked 
aneurysms are often contraindications for various treatments, so these could be used for 
developing devices that are effective in treating these disease states. For example, these 
aneurysms could be used to test the effectiveness of coils or liquid embolics in conjunction with 
stents or flow diverters. The flow diverters could prevent the ejection of the device inside of the 
aneurysm, effectively treating the aneurysm with multiple complementary devices. Further work 
will need to be performed to determine applicability of the model for this use. 
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CHAPTER 5 
CONCLUSIONS 
This project shows the process of building up research capabilities regarding liquid embolic use 
and particulate characterization. It covers the design of an in vitro flow model, multiple methods 
of counting and analyzing microscopic particles, and the development of an in vivo model to test 
liquid embolics and other aneurysm treatment devices. A variety of different techniques have 
been used that encompass the fields of physics, engineering, and biology. This has clarified the 
level of embolic risk from PPODA-QT from both an engineering and medical approach. A 
summary of the findings from each aim and its implication in answering the hypotheses are 
discussed below: 
Aim 1 - Develop an in vitro model that mimics human physiological and 
anatomical conditions 
An in vitro model was successfully created to practice and imitate endovascular surgery. It can 
successfully simulate physiologically-relevant vascular pressures, temperatures, and flow rates, 
and customizable inserts can be used to recreate various anatomies for different disease states. 
This model was used primarily with models designed for straightforward access and 
anatomically-relevant aneurysms so that rapid testing of PPODA-QT and other 
neuroendovascular devices could be performed. It contains a filter system that can be used to 
capture downstream particles and assess devices for embolic risk. 
Further studies will incorporate more sophisticated monitoring sensors and data acquisition 
hardware, which will make the physiological condition monitoring more accurate and user-
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friendly. In addition, new anatomies and model types can be incorporated into the model to test 
in various disease states. 
Aim 2 - Use the aforementioned in vitro model and different microscopy 
techniques to characterize the shape and number of liquid embolic particles 
released during aneurysm embolization 
Microscopic techniques were developed to assess downstream particulation during endovascular 
procedures. SEM was initially used to understand basic distinguishing characteristics of various 
PPODA-QT particles so that differences between independently-formed and broken particles 
could be distinguished. Then a method of DIC microscopy, MATLAB, and ImageJ analysis was 
developed to count total particle sizes and numbers to confirm USP <788> conformation for 
various materials. Finally, an inline digital holography setup was created to be used for future 
non-invasive particle analysis. 
Future Work 
Further work will be done by the BDL to improve these test methods. Initial studies show that 
the filters primarily capture contamination, so further preparation, such a cleanroom setup, must 
be developed to remove contamination from the system. In addition, using off the shelf 
microcatheters and neurovascular balloon catheters rather than ones made in the lab could reduce 
issues such as the PPODA-QT sticking that was observed in initial tests.   
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Aim 3 - Develop an in vivo rabbit aneurysm model that can eventually be used 
to evaluate liquid embolic efficacy and safety 
A rabbit aneurysm model was developed in order to test various treatment methods. While some 
initial embolizations were attempted, the purpose of this study was primarily to develop the 
aneurysm itself. Various aneurysm sealing procedures, elastase mixtures, and access routes were 
used, and an endovascular approach with balloon occlusion and elastase in 9pH PBS was the 
final iteration. Further studies with this new approach will be used to evaluate PPODA-QT’s 
embolic efficacy. 
Future Work 
More studies will need to be performed in order to test PPODA-QT as a viable aneurysm 
treatment device. These tests can begin once saccular aneurysms are created. In addition, elastase 
concentration and solvents could be varied to test their effects on aneurysm shape and size. 
Finally, the model still has the potential to be used in other disease states, such as wide-necked 
aneurysm treatment. 
Hypothesis 1 - An in vitro system that mimics human physiological and 
anatomical conditions can be built to test liquid embolic conformation to the 
USP <788> 
Initial results show that the model can simulate physiological conditions, and a method has been 
developed to analyze downstream particulation during procedures. However, the hypothesis must 
be rejected for now because further studies must be performed in order to finalize the counting 
method in either DIC microscopy or inline digital holography. After this is done, USP <788> 
testing can commence for PPODA-QT and other devices. 
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Hypothesis 2 - An in vivo aneurysm model can be developed to evaluate liquid 
embolic without observed negative embolic effects 
This hypothesis must also be rejected because liquid embolic treatment of physiologically-
accurate aneurysms has not yet been performed. The model has been developed and ongoing 
studies hope to successfully create an accurate aneurysm that can simulate a naturally-occurring 
saccular aneurysm. Then it can be used to assess PPODA-QT and other treatment options. 
However, the model as it stands today could potentially be used for harder to treat wide-necked 
aneurysms, providing a new model for device testing.  
Limitations and Further Research 
While this large study covers many aspects of liquid embolic particulation analysis, there are 
significant limitations and areas for improvement. As outlined above, contamination issues must 
be remedied to fully adhere to the USP <788> standard. This could be accomplished via a 
cleanroom setup or performing the full USP <788> characterization with non-invasive inline 
digital holography. Performing the study non-invasively has the potential to minimize 
contamination in handling, and it can also be performed live for shorter analysis. Once the in 
vivo model is finalized, the safety confirmed in the in vitro model can be verified in a living 
model. This two-sided approach will present a full understanding of the absolute and practical 
results of liquid embolic particulation, enabling the lab to create safer, better medical devices. 
Final Flow Loop Design and Particle Counting Approach 
Over the course of this thesis work, an ideal flow loop system has been conceptualized. To 
simplify the physiological condition maintenance, more advanced data acquisition systems could 
be used. A National Instruments Input Module (NI 9201) and Thermocouple Module (NI 9213) 
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could be housed in a chassis (cDAQ-9174), and the combination of these would eliminate the 
power supply and signal amplification box. This would also enable the VI to be run at higher 
sampling frequencies. The same pressure transducers and thermocouples could be used, but a 
new analog flow meter would address the sampling issues found with the current digital one. 
More physiologically-relevant model materials could improve stiffness and endovascular surface 
properties. Studies to explore new or existing materials that will more closely mimic vascular 
compliance would be valuable to identify better candidates than the polyurethane resin used here. 
Further cleaning and smoothing of the model core could also be used to smooth the endovascular 
surface of the model.  
A more advanced programmable pump, such as the Biomedical Device Consultants (BDC) PD-
1100, could be used to mimic physiological waveforms more accurately than the current pump.64 
Housing the entire system in a particulate hood or cleanroom could alleviate contamination 
issues. 
Finally, a non-invasive live counting device would be ideal for USP <788> testing. A light 
extinction or scattering method such as the Eaton CCM 01 Contamination Control Monitor Set 
could be incorporated into the system.65 This would enable live counting of particles non-
invasively, improving accuracy, timeliness, and reliability. 
A combination of these improvements has the potential to drastically improve the in vitro model 
and particle counting system. By incorporating these changes, the BDL could drastically improve 
the speed and accuracy of its testing. This would enable the BDL to develop safer devices even 
faster, streamlining the way towards helping improve lives around the world. 
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APPENDICES 
APPENDIX A 
IN VITRO MODEL DIAGRAMS 
This appendix lays out the sensor specifications, electrical amplification circuits, and software 
diagrams. First are the specification sheets: 
Pressure Transducers47 
Deltran® Disposable Pressure Transducer 
Continuous Flow Rate (for models with integral 
flush device) 
3cc/hr (+2/-1cc/hr) or 30cc/hr (± 10cc/hr) at 300 mmHg 
Operating Pressure Range -50 to +300 mmHg 
Sensitivity 5 µV/V/mmHg, ±2% (typically < ±1%) 
Zero Drift With Time 
< ±1.0 mmHg/8 hours after 10 min. warm-up to operating 
temperature 
Leakage Current <2 µA @ 115 Vac rms at 60 Hz 
Unbalance ±75 mmHg 
Overpressure Protection -400 to +4000 mmHg 
Operating Temperature 15° C to 40° C 
Excitation Voltage and Frequency 2 to 10 Vdc; or Vac rms to 5 kHz 
Operating Life >500 hours 
Storage Temperature -25° C to +65° C 
Defibrillation Withstand 5 discharges/5 minutes of 400 joules @ 50 ohm load 
Natural Frequency >200 Hz in saline 
Phase Shift <5° at 5 kHz 
Output Impedance 270 Ohms to 400 Ohms 
Input Impedance 270 Ohms to 400 Ohms 
 
 
 
 
 
69 
 
Thermocouple (Reference Table for General K-Type Thermocouples)48  
 
 
 
 
 
 
 
70 
 
Flow Meter49  
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Next are the signal amplification circuits that are housed in the Signal Amplification Box: 
Pressure Transducers, Thermocouples, and Flow Meters (respectively:  
 
Figure A- 1 22x gain inverting circuit for the pressure transducer 
 
Figure A- 2 484x gain inverting circuit for the thermocouple 
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Figure A- 3 Voltage splitting circuit for the flow meter 
 
 
 
 
 
 
 
 
 
 
73 
 
Here is the Signal Amplification Box bill of materials as well as images of the setup:  
Table A- 1 Components used in the Signal Amplification Box 
Signal Amplification Box Component List 
Sub-Assembly 
Component 
Name 
Source P/N 
Quantity per 
Circuit 
Pressure 
Transducer 
Amplification 
(4 Circuits) 
220Ω, 1/4W 
Resistor 
Digi-Key CF14JT220RCT-ND 1 
10kΩ, 1/4W 
Resistor 
Digi-Key CF14JT10kOCT-ND 1 
LM741CN 
Op-amp 
Digi-Key LM741CNNS/NOPD-ND 1 
8-Pin Holder Digi-Key AE9986-ND 1 
 
Thermocouple 
Amplification 
(2 Circuits) 
220Ω, 1/4W 
Resistor 
Digi-Key CF14JT220RCT-ND 2 
10kΩ, 1/4W 
Resistor 
Digi-Key CF14JT10kOCT-ND 2 
LM741CN 
Op-amp 
Digi-Key LM741CNNS/NOPD-ND 2 
8-Pin Holder Digi-Key AE9986-ND 2 
 
Flow Meter 
Amplification 
(2 Circuits) 
100kΩ, 1/4W 
Resistor 
EE Shop Unsure 2 
10kΩ, 1/4W 
Resistor 
Digi-Key CF14JT10kOCT-ND 1 
 
Signal 
Amplification 
Box 
4 Position 
Wire Terminal 
Block 
Digi-Key ED2877-ND 8 
Female 
Banana Plug 
Digi-Key 
J150-ND (White), J151-ND (Red), 
J152-ND (Black), J153-ND (Green) 
1 of each 
4-40, 1-1/2” 
Machine 
Screw 
McMaster-
Carr 
91781A119 4 
4-40 Nut 
McMaster-
Carr 
91841A005 4 
Solderable 
Breadboard 
Ebay SB404 2 
Box Bottom MakerLab NA 1 
Box Top MakerLab NA 1 
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Figure A- 4 Breadboards used inside the Signal Amplification Box. The top image shows the 4 pressure transducer circuits 
(Figure A- 1), and the bottom shows the 2 thermocouple amplification circuits in the left and middle (Figure A- 2), as well as the 
flow meter circuit on the right (Figure A- 3) 
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Figure A- 5 Wiring diagram for the signal amplification box. The Power Side uses female banana plug inputs, and the other sides 
use wire screw block terminals 
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Here are screenshots of the LabVIEW program Block Diagram that controls the in vitro flow 
model parameters: 
    
Figure A- 6 Part 1 of 3 of Flow Loop Monitor VI block diagram. This is where channels are activated or closed, data is 
collected, and some initial filtering of outliers is done for the flow meters. 
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Figure A- 7 Part 2 of 3 of Flow Loop Monitor VI block diagram. This is where the automatic calibration structures are located, 
calibration lines are calculated, and the option is given to transfer the automatic calibration values to manual calibration mode. 
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Figure A- 8 Part 3 of 3 of Flow Loop Monitor VI block diagram. This is where the values are averaged for graphing and display 
on the charts. The bottom structure is where data is recorded to a .csv file. 
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Table A- 2 All data taken during 5µm filter trials with polypropylene standard spheres as well as PPODA-QT 
  Proximal Pressure (mmHg) Distal Pressure (mmHg)   
Material 
Number 
of 
Spheres 
Trial 
Time 
(min) 
Min Max Mean 
Devi 
ation 
Min Max Mean 
Devi 
ation 
Flow 
Rate 
(mL/ 
min) 
Temp 
(°C) 
Poly 
propylene 
Spheres 
0 
1 
0 69 199 140 65 12 42 26 15 222 37-
40 20 140 182 160 21 -1 53 30 27 214 
2 
0 110 141 127 15 9 24 18 8 235 37-
40 20 130 165 148 18 19 35 27 8 222 
Poly 
propylene 
Spheres 
1500 
1 
0 119 152 138 16 21 38 30 8 235 37-
40 20 133 167 152 17 27 33 29 3 222 
2 
0 113 156 134 22 13 40 29 14 235 37-
40 20 146 157 152 5 18 21 19 2 222 
Poly 
propylene 
Spheres 
3000 
1 
0 114 147 132 16 13 32 21 10 231 37-
40 20 94 187 150 46 23 45 33 11 222 
2 
0 86 177 139 45 17 46 33 14 235 37-
40 20 100 181 149 41 18 35 28 8 226 
Poly 
propylene 
Spheres 
4500 
1 
0 82 185 139 51 18 45 32 13 235 37-
40 20 77 177 131 50 5 32 17 13 226 
2 
0 81 179 137 49 18 40 29 11 231 37-
40 20 89 159 130 35 8 29 20 11 222 
PPODA-
QT 
NA 
1 
0 54 154 113 50 14 36 26 11 119 37-
40 20 62 166 123 52 11 38 27 13 113 
2 
0 59 172 122 56 15 33 25 9 117 37-
40 20 59 188 126 64 14 44 29 15 106 
3 
0 46 173 118 63 10 38 26 14 113 37-
40 20 64 171 125 53 10 40 28 15 105 
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APPENDIX B 
IMAGEJ AND MATLAB COUNTING PROGRAM 
This appendix and code explanation was written by Kevin LoGrande. 
 
%Automated Particle Analysis 
%Author: Kevin A LoGrande 
%Last Updated: 04-21-2018 
  
%This code is used for the automated particle analysis of z-stacks in ImageJ. 
%The user inputs basic information about the trial and sets a scale, then  
%the code automatically opens images, stacks them, and counts the particles. 
%The code outputs the number of particles over 10 and over 25 microns. 
  
%Notes: 
%1. All images must be named as follows: mm-dd-yy-trial#-stack#-image#.tif 
%   (e.g. 03-03-18-trial2-stack1-image5.tif) 
%2. The miji.m script must be ran first to ensure interfacing between 
%   imageJ and MATLAB 
  
%first, we initialize the particle counts at zero 
micron25=0; 
micron10=0; 
  
%user inputs date, trial number,  number of stacks, and stack size 
date = input('Input the date in the format mm-dd-yy\n','s'); 
trial = input('Input the trial number.\n'); 
StackSize = input('Input the number of z heights.\n'); 
GridSize = input('Enter the number of images in the grid.\n'); 
  
%image analysis for various stacks 
for image = 0:GridSize 
      
    %automatically opens the images to be analyzed if they follow the 
    %naming convention 
    for stack = 0:StackSize 
        MIJ.run('Open...',sprintf('path=[%s-trial%i-stack%i-image%i.jpg]', 
date, trial, stack, image)) 
    end 
     
    %uses ImageJ to stack the images and project them to a single image 
    MIJ.run('Images to Stack') 
    MIJ.run('Z Project...','projection=[Min Intensity]') 
     
    %on the first stack, the user sets a known scale to be applied to the 
    %rest of the stacks 
    if image == 0 
        scale = input('Draw a line of known length in ImageJ, then press 
enter.\n'); 
        MIJ.run('Set Scale...') 
    end 
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    %Sets a threshold that eliminates filter pores, but includes particles 
    MIJ.run('8-bit') 
    MIJ.setThreshold(100,255); 
    MIJ.run('Make Binary') 
     
    %ImageJ analyzes particles, then passes the results to MATLAB to count 
    %particles over 10 microns and over 25 microns. 
    MIJ.run('Analyze Particles...','size=80.0-Infinity circularity=0.0-1.0 
show=[Nothing] display clear include') 
 
    data=MIJ.getResultsTable; 
    [rows,columns]=size(data); 
 
    for i=1:rows 
        if data(i,2)>=25 
            if data(i,2)/data(i,3)>2 
 
                micron25=micron25+1; 
 
        elseif data(i,2)>=10 
 
                micron10=micron10+1; 
        end 
    end 
 
    %close images after counting particles to save memory space 
    MIJ.run('Close All') 
End 
 
%Printng analysis results. 
fprintf('There are %i particles larger than 10 microns and %i particles 
larger than 25 microns\n',micron10,micron25) 
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Some of the commands are explained below. 
MIJ.run('Z Project...','projection=[Min Intensity]') 
After the images are open and stacked, this function projects a single image based on the 
minimum intensity of light at each pixel. This makes the pores dimmer than the particles. The 
original images, as well as the result are shown below. 
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    if image == 0 
        scale = input('Draw a line of known length in ImageJ, then press 
enter.\n'); 
        MIJ.run('Set Scale...') 
    end 
 
The MATLAB variable “scale” is not important and isn’t used. This just acts as a delay, telling 
the user to draw a line using the ImageJ command window. I have been using the non-blurred 
axis of a pore as the line of known length. I zoom in and draw a line across the pore. A visual is 
shown below. 
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After the line is drawn, as per the instructions of the code, you press enter. (Note: this will store a 
zero in to the variable “scale”, but again this is not a used variable.) Now that a line is drawn the 
set scale command opens the dialog box shown below. 
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The distance in pixels is automatically filled from the line we 
drew. We know this distance is 5 microns. I make sure to click 
the “global” check box to ensure this scale is applied to every 
subsequent image. 
 
 
    MIJ.run('8-bit') 
    MIJ.setThreshold(60,255); 
    MIJ.run('Make Binary') 
 
This set of commands converts the image to an 8-bit gray scale image, then sets a threshold and 
converts to binary (black and white). Visuals for this process are shown below. 
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    MIJ.run('Analyze Particles...','size=80.0-Infinity circularity=0.0-1.0 
show=[Nothing] display clear include') 
 
The “analyze particles” command would generally 
open the dialog box shown, but by defining all keys in 
the code, the dialog box is automatically filled in. Note 
that in this image I have “show: oulines.” This is not 
the case in the code, but for purposes of visualizing 
results, I have included it here. The image of the 
outlined particles as well as the results table is shown 
below. 
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  data=MIJ.getResultsTable; 
This command passes the data table shown on the 
left to a MATLAB array (I named the array 
“data”). Only the actual data is passed, not the 
number of the particle. Therefore the MATLAB 
array is 24x4 in size with the first column being 
“area.” The remaining code just manipulates the 
data array and adds to the particle counts. 
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APPENDIX C 
RABBIT PROCEDURE MATERIALS 
Rabbit Elastase Aneurysm Creation Procedure Materials 
▪ Ketamine/Xylazine/Acepromazine at 60/6/1 mg/kg  
▪ Isofluorine (1-1.5% in O2 at ~1 L/min) 
▪ 1x Clippers 
▪ Blunt dissection/access tools 
▪ 1x Surgical Clip 
▪ Sutures 
▪ 5F introducer 
▪ 3F Fogarty balloon catheter 
▪ 1x shortened microcatheter 
▪ 1x Sterile Filter 
▪ 80U Elastase (Worthington Biochemical Corporation, Lakewood, NJ) 
▪ 9pH PBS 
▪ 1x 1mL syringe 
 
PPODA-QT Aneurysm Embolization Procedure Materials 
Surgical Materials 
▪ Ketamine/Xylazine/Acepromazine at 60/6/1 mg/kg  
▪ Heparin 
▪ Lidocaine 
▪ Isofluorine (1-1.5% in O2 at ~1 l/MIN) 
▪ Surgical drape 
▪ Iodine 
▪ Alcohol wipes 
▪ Blunt Dissection/access tools 
▪ Catheter lidocaine lube 
▪ 1x 5F introducer 
▪ Scissors 
▪ Saline 
▪ 1x Introducer stabilization suture 
▪ 1x 5F angiocatheter 
▪ 2x Y-Tuohy Borst 
▪ Contrast (Isovue) 
▪ 1x ~20.5G needle 
▪ Fluoroscope ruler or micrometer 
▪ 1x Guidewire ~0.010” 
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▪ 1x Scepter Balloon Catheter ~3.0-4.0mm OD 
▪ 3x 1mL Polycarbonate syringes  
▪ 1x 3mL Polypropylene syringes 
▪ 1x Microcatheter (Codman Prowler and Velocity Penumbra were used) 
▪ Blood vessel repair kit 
▪ Closure sutures 
▪ Wound closure adhesive 
▪ 4x 3-way Stopcocks 
 
PPODA-QT Preparation Materials 
▪ 1x 3mL PP syringe with 1.080g + Dead Volume PPODA 
▪ 1x 3mL PP syringe with 0.330g +Dead Volume QT 
▪ 11.00pH Conray 
▪ 1x 1mL PC syringe (for 0.46mL Conray) 
▪ 1x ~22.75G needle for Conray 
▪ 2x Female-Male 0.2µm syringe filter 
▪ 2x Female-female connector 
▪ 2x 3mL PP syringe 
▪ 1x Male-male connector 
▪ 1x Injection syringe 
▪ 1x Injection wings 
 
 
 
